Evidence map›Paper›PMID 33736946›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2021

Diagnostic performance of a SARS-CoV-2 rapid antigen test in a large, Norwegian cohort.

Elisabeth Toverud Landaas, Margrethe Larsdatter Storm, Mette Christophersen Tollånes, Regine Barlinn, Anne-Marte Bakken Kran, Karoline Bragstad, Andreas Christensen, Trude Andreassen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Guideline
  3. Pooled it
  4. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Differential clinical characteristics and performance of home antigen tests between parents and children after household transmission of SARS-CoV-2 during the Omicron variant pandemic.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elisabeth Toverud LandaasDepartment of Microbiology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: eltlan@ous-hf.no.
Margrethe Larsdatter StormDivision of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
Mette Christophersen TollånesNorwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, Bergen, Norway; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Regine BarlinnDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Anne-Marte Bakken KranDivision of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
Karoline BragstadDivision of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
Andreas ChristensenDivision of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway; Department of Medical Microbiology, St. Olav's Hospital, Trondheim, Norway.
Trude AndreassenNorwegian Directorate of Health, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRapid antigen tests (RATs) may be included in national strategies for handling the SARS-CoV-2 pandemic, as they provide test results rapidly, are easily performed outside laboratories, and enable immediate contract tracing. However, before implementation further clinical evaluation of test sensitivity is warranted.

objectivesTo examine the performance of Abbott's Panbio™ COVID-19 Ag Rapid Test Device for SARS-CoV-2 testing in a low to medium prevalence setting in Norway. STUDY

designA prospective study comparing the results of the Panbio RAT with PCR in 4857 parallel samples collected at a SARS-CoV-2 test station in Oslo, and from COVID-19 outbreaks in six Norwegian municipalities.

resultsA total of 4857 cases were included in the study; 3991 and 866 cases from the test station and the outbreak municipalities, respectively. The prevalence at the test station in Oslo was 6.3 %, and the overall sensitivity of the RAT was 74 %. Increased sensitivity was observed in patients who experienced symptoms (79 %) and when considering samples with viral loads above estimated level of infectivity (84 %), while it was lower in asymptomatic persons (55 %). In the outbreak municipalities, the overall prevalence was 6.9 %, and the total sensitivity of the RAT was 70 %.

conclusionsOur results indicate that the test correctly identified most infectious individuals. Nevertheless, the sensitivity is considerably lower than for PCR, and it is important that the limitations of the test are kept in mind in the follow-up of tested individuals.

Indexed as

Antigens, ViralCOVID-19COVID-19 Serological TestingCOVID-19 TestingFalse Negative ReactionsFalse Positive ReactionsHumansNorwayProspective StudiesSARS-CoV-2Sensitivity and SpecificityViral LoadAntigens, ViralCoronavirusCOVID-19Lateral flow assay (LFA)Point-of-care test (POCT)Rapid antigen test (RAT)SARS-CoV-2

Identifiers

PMID33736946
PMCPMC7944803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.